Business
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and
About this update from Novartis Ag
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report prognostic and predictive impact of gene expression from largest biomarker CDK4/6i trial datasetScemblix® ASC4FIRST oral presentation to feature longer-term 144-week efficacy, safety and tolerability data in first-line Ph+ CML-CPNew Novartis pipeline data, including Phase 3 ianalumab in ITP as well as Phase 1 actinium-based radioligand therapy, also to be presentedBasel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress. “We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT,” said Mark Rutstein, MD, Global Head, Oncology Development, Novartis. “With a legacy of bold science, our Kisqali and Scemblix data offer continued evidence of how we meaningfully move cancer treatment forward for patients.” Key ASCO data highlights include: Abstract Title Abstract Number/ Presentation Details Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Subgroup Analyses by Disease Volume and De Novo/Recurrent mHSPC in the PSMAddition Study of [177Lu]Lu-PSMA-617 225Ac-PSMA-617AcTION: Phase 1 Study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With or Without Prior [177Lu]Lu-PSMA (177Lu-PSMA) Radioligand Therapy (RLT) Abstract # 5020Rapid OralMay 31, 4:30pm – 6:00pm CDT Abstract # 5010OralJune 1, 3:00pm – 4:30pm CDT Scemblix (asciminib) ASC4FIRST wk 144 Analysis: Efficacy and Safety and Tolerability With Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed (ND) chronic myeloid leukemia in Chronic Phase (CML-CP) Abstract #6583PosterJune 1, 9:00am – 12:00pm CDT Kisqali (ribociclib) Prognostic and Predictive Impact of Baseline Gene Expression (Exp) in the NATALEE Trial of Adjuvant (Adj) Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in HR+/HER2− Early Breast Cancer (EBC) Abstract #501OralMay 30, 1:15pm – 4:15pm CDT Real-World (RW) Post-Progression ...